文献速递银屑病与炎症性皮肤病

生物制剂改善亚临床银屑病关节炎滑膜炎与附着点炎的12周真实世界研究

Effectiveness of biologics on synovitis and enthesitis using musculoskeletal ultrasound assessment in subclinical psoriatic arthritis: A 12-week observational real-world study.
PubMed 文献 · J Am Acad Dermatol · 2025-09-08

本研究为多中心、观察性、前瞻性真实世界研究,从178例无关节症状的中重度银屑病患者中用肌骨超声筛查出22例亚临床银屑病关节炎(Sub-PsA)患者,所有患者接受首次生物制剂治疗,12周后复查超声评估滑膜炎与附着点炎变化。结果显示滑膜炎与附着点炎总评分从第0周的12.5(4.1)降至第12周的8.4(2.8)(P < .001),小关节滑膜炎评分从10.5(3.8)降至6.9(2.5)(P < .001)。结论认为生物制剂短期可显著改善Sub-PsA患者的关节滑膜炎与附着点炎,尤其对小关节滑膜炎。

要点

  • 肌骨超声可在无关节症状的中重度银屑病患者中筛查出亚临床银屑病关节炎。
  • 生物制剂治疗12周可显著降低Sub-PsA患者滑膜炎与附着点炎评分。
  • 小关节滑膜炎改善尤为明显,短期疗效显著。

核心结论

  • 生物制剂治疗可显著改善亚临床银屑病关节炎患者的关节滑膜炎和附着点炎,短期尤其对小关节滑膜炎有效。

研究设计与样本

  • 多中心、观察性、前瞻性真实世界研究,从178例无关节症状的中重度银屑病患者中经肌骨超声筛查出22例亚临床银屑病关节炎患者,所有患者接受首次生物制剂治疗,12周后重复肌骨超声评估。

主要发现

  • 滑膜炎与附着点炎总评分从第0周的12.5(4.1)降至第12周的8.4(2.8)(P < .001)。
  • 小关节滑膜炎评分从第0周的10.5(3.8)降至第12周的6.9(2.5)(P < .001)。

临床怎么用

  • 对无关节症状的中重度银屑病患者可考虑肌骨超声筛查亚临床关节炎,生物制剂短期治疗可能改善超声下滑膜炎与附着点炎。

局限性

  • 样本量有限可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriatic arthritis (PsA) is a condition that can lead to permanent joint deformities. It is crucial to find ways to prevent psoriasis from progressing to PsA. OBJECTIVE: To observe the short-term efficacy of biologics on synovitis and enthesitis in subclinical psoriatic arthritis (Sub-PsA) using musculoskeletal ultrasound. METHODS: This study is a multicenter, observational, prospective real-world study. Sub-PsA patients were screened from patients with moderate to severe psoriasis without joint symptoms using musculoskeletal ultrasound. All patients received their first biologic treatment, and musculoskeletal ultrasound was repeated after 12 weeks to assess changes in joint synovitis and enthesitis. RESULTS: Among 178 enrolled moderate to severe psoriasis patients without joint symptoms, 22 Sub-PsA patients were identified. At week 0, the synovitis and enthesitis scores were 12.5 (4.1), decreasing to 8.4 (2.8) by week 12 (P < .001). At week 0, the small joint synovitis score was 10.5 (3.8), which reduced to 6.9 (2.5) by week 12 (P < .001). LIMITATIONS: Limited sample size may introduce bias. CONCLUSION: Biologics treatment can significantly improve joint synovitis and enthesitis in Sub-PsA patients in the short term, especially for small joint synovitis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Liu Z, Chen J, Zhou K, et al. Effectiveness of biologics on synovitis and enthesitis using musculoskeletal ultrasound assessment in subclinical psoriatic arthritis: A 12-week observational real-world study. J Am Acad Dermatol. 2025. PMID: 40930421. doi:10.1016/j.jaad.2025.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。